Expand into Europe: unlocking the orphan drug market
The European orphan drug market is growing rapidly, offering U.S. biotech companies a significant opportunity to expand into Europe. However, navigating the region’s complex regulatory, pricing, and reimbursement landscapes requires a strategic approach.
In this exclusive guide, we cover:
- Key regulatory pathways and market entry considerations for orphan drugs in Europe
- How to leverage early access programs and real-world data for market adoption
- The benefits of partnering with European specialists to streamline distribution and compliance
- Best practices for patient engagement, advocacy, and long-term market success
Download this guide to learn how to successfully commercialize your orphan drug and expand into Europe, ensuring both patient impact and commercial viability.
About Sciensus
Sciensus is a European leader in integrated end-to-end commercial services, supporting patients, health systems, providers and Biopharma companies. We offer distribution services, clinical care, digital solutions and patient insights to accelerate access to medicines and maximise product launches from clinical to full commercialisation. With over 30 years’ experience navigating the complex European healthcare ecosystem, Sciensus helps bring the right medicine to the right patients – faster.
